CLINICAL_TRIALS
trial_result
· 2025-07-23
Clinical Trial Update: First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]
Summary
First-in-human Phase 1 dose-escalation study of AFM28 in relapsed/refractory acute myeloid leukemia; the trial status is TERMINATED.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Affimed GmbH | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED